Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glioma of Brain Clear all
Terminated Phase 1 Interventional

VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma

NCT00516282
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
CLORETAZINE, temozolomide
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced Jul 23, 2026, 5:30 AM EDT
Terminated No phase listed Observational

(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas

NCT01281982
View directory record Official record
Conditions
Low Grade Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Oligoastrocytoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain

NCT00003348
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT00553150
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
everolimus, temozolomide, radiation
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
178
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 115 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Jul 23, 2026, 5:30 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors

NCT04479696
View directory record Official record
Conditions
Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions
Educational Intervention, Questionnaire Administration, Survey Administration, Video
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer

NCT01048008
View directory record Official record
Conditions
Advanced Cancer, Brain Involvement
Interventions
DM-CHOC-PEN
Drug
Lead sponsor
DEKK-TEC, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma

NCT00293423
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
HSPPC-96, Standard Surgical Resection
Biological · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
3
States / cities
San Francisco, California • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Jul 23, 2026, 5:30 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

NCT00626990
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, DNA methylation analysis, laboratory biomarker analysis, adjuvant therapy, quality-of-life assessment, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years to 120 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
72
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Jul 23, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional Results available

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

NCT01068782
View directory record Official record
Conditions
Astrocytic Tumors
Interventions
Cabozantinib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Encinitas, California • Pleasant Hill, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 23, 2026, 5:30 AM EDT
Recruiting Phase 2 Interventional

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

NCT03175224
View directory record Official record
Conditions
Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Interventions
APL-101 Oral Capsules
Drug
Lead sponsor
Apollomics Inc.
Industry
Eligibility
18 Years and older
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Jul 23, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional

Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors

NCT00848523
View directory record Official record
Conditions
Recurrent Malignant Gliomas
Interventions
Panobinostat
Drug
Lead sponsor
Neurological Surgery, P.C.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Commack, New York • Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2010 · Synced Jul 23, 2026, 5:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

NCT04923126
View directory record Official record
Conditions
Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma
Interventions
Mirdametinib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 24 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 23, 2026, 5:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Development of MR Spectroscopy and Imaging in Brain Cancers

NCT02731521
View directory record Official record
Conditions
Malignant Gliomas, Astrocytomas, Oligodendrogliomas
Interventions
3 Tesla Scanning, 7 Tesla Scanning
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

NCT00613132
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Gleevec, RAD001, and Hydroxyurea
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 4 Interventional

Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy

NCT02193568
View directory record Official record
Conditions
Adult Brain Tumor
Interventions
Arm I (light sedation), Arm II (intubated general anesthesia), Arm II (intubated general anesthesia), Arm I (light sedation)
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy

NCT00030108
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Leukemia, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ixabepilone
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
2 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jul 23, 2026, 5:30 AM EDT
Withdrawn Phase 3 Interventional

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

NCT00226668
View directory record Official record
Conditions
Brain Edema, Brain Tumor
Interventions
hCRF, placebo hCRF
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2008 · Synced Jul 23, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional Results available

Sunitinib to Treat Recurrent Brain Cancer

NCT00923117
View directory record Official record
Conditions
Glioblastoma Multiforme, Malignant Gliomas, Anaplastic Gliomas
Interventions
Sutent (sunitinib)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

NCT02502708
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor, Ependymoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Primary CNS Tumor
Interventions
Indoximod, Temozolomide, Conformal Radiation, Cyclophosphamide, Etoposide
Drug · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
3 Years to 21 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Aurora, Colorado • Orlando, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

Vandetanib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Diffuse Brainstem Glioma

NCT00472017
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
vandetanib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2012 · Synced Jul 23, 2026, 5:30 AM EDT
Active, not recruiting Phase 1 Interventional

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

NCT00268385
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Vorinostat
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

NCT00492089
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Central Nervous System Germ Cell Tumor, Adult Choroid Plexus Tumor, Adult Diffuse Astrocytoma, Adult Ependymoma, Adult Grade II Meningioma, Adult Grade III Meningioma, Adult Malignant Hemangiopericytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pineocytoma, Malignant Neoplasm, Meningeal Melanocytoma, Radiation Toxicity, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage I Adenoid Cystic Carcinoma of the Oral Cavity, Stage I Basal Cell Carcinoma of the Lip, Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage I Lymphoepithelioma of the Nasopharynx, Stage I Lymphoepithelioma of the Oropharynx, Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage I Mucoepidermoid Carcinoma of the Oral Cavity, Stage I Salivary Gland Cancer, Stage I Squamous Cell Carcinoma of the Hypopharynx, Stage I Squamous Cell Carcinoma of the Larynx, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Nasopharynx, Stage I Squamous Cell Carcinoma of the Oropharynx, Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage I Verrucous Carcinoma of the Larynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Basal Cell Carcinoma of the Lip, Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions
bevacizumab, placebo, magnetic resonance imaging, quality-of-life assessment
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jul 23, 2026, 5:30 AM EDT
Terminated Phase 1 Interventional

Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors

NCT01902771
View directory record Official record
Conditions
Glioma, Brain Cancer, Brain Tumor, Glioblastoma Multiforme, High Grade Glioma
Interventions
Dendritic Cell Vaccine, Tumor Lysate, Imiquimod, Leukapheresis
Biological · Other · Procedure
Lead sponsor
Edward Ziga
Other
Eligibility
1 Year to 29 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Jul 23, 2026, 5:30 AM EDT
Completed No phase listed Observational

DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma

NCT00899834
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
3
States / cities
Palo Alto, California • Memphis, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Jul 23, 2026, 5:30 AM EDT